



11-06-03

EV 129870417

1645  
Image

**PATENT**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**  
(Case No. API-01-059-US)

**In the Application of:** **Robert P. Ryall** )

)  
)  
)  
) **Examiner: Devi, S JN**

**Serial No.:** **10/054,638** )

) **Art Unit: 1645**

**Filed:** **01/22/2002** )

**For: Multivalent Meningococcal Polysaccharide-** )  
**Protein Conjugate Vaccine** )

**INFORMATION DISCLOSURE STATEMENT**

Asst. Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Applicants respectfully submit this Information Disclosure Statement, PTO-1449 and copies of the reference cited therein. This Information Disclosure Statement is in compliance with the duty of candor as set forth in 37 C.F.R. § 1.56. It is requested that the documents be given careful consideration and that they be cited of record in the prosecution history of the present application so that they will appear on the face of the patent issuing of the present application.

In the judgment of the undersigned, portions of the references may be material to the examination of the pending claims. However, the references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative importance of any portion of the references. This Statement is not a representation that the cited references are "prior art" within the meaning of 35 U.S.C. §102 or §103.



**U.S. Patents**

**CITED REFERENCES**

**Foreign Patent Documents**


**Other Documents:**

LINDBERG: Glycoprotein conjugate vaccines: Vaccine 17 (1999) Pages S28-S36

Respectfully Submitted,  
AVENTIS PASTEUR INC.

Date: Nov. 5, 2003

By: *T. Helen Payne*  
T. Helen Payne  
Reg. No. 36,889



Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

*(Use as many sheets as necessary)*

Application Number	10/054,638
Filing Date	01/22/02
First Named Inventor	Robert P. Ryall
Art Unit	1645
Examiner Name	Devri, Sarvamangala
Attorney Docket Number	API-01-059-US

[illegible][illegible]

Date	
Considered	

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*



EV 129870417

PTO/SB/08B (02-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/054,638
Filing Date	01/22/2003
First Named Inventor	Robert P. Ryall
Art Unit	1645
Examiner Name	Devi, Sarvamangala
Attorney Docket Number	API-01-059-US

Sheet	2	of	2
-------	---	----	---

**OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		LINDBERG: Glycoprotein conjugate vaccines: Vaccine 17 (1999) Pages S28-S36	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.